Biotech KPO

biotechkpo.com

Biotech KPO specializes in outsourcing of Business Process that creates value for our clients. We help our clients optimize business process enhancing flexibility of their operation at substantial cost advantage. The company focuses on the high-end Biotechnology/ Life Sciences services. The services we provide are highly knowledge based, require highly skilled professionals and cover some of the critical knowledge management areas for our clients. Biotech KPO, team of Biotechnology Professional, providing these services from our state-of-art facility in New Delhi-India. India is a promising source of supply for talent for providing these services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

Cell and Gene Therapy

ORANGEWOOD PARTNERS MAKES STRATEGIC INVESTMENT IN BARRINGTON JAMES

Orangewood and Barrington James | October 06, 2022

news image

Orangewood Partners a long-term focused private investment firm, announced an investment in Barrington James, a leading global recruitment firm that primarily serves the pharmaceutical, biotechnology and medical device sectors. Terms of the transaction were not disclosed. In partnering with Orangewood, Barrington James intends to enhance its global recruiting solutions, expand its client-service capabilities and support its ongoing commitment to developing and utilizing cutting-ed...

Read More

MedTech

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

news image

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More

Industrial Impact

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

news image

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More
news image

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

Cell and Gene Therapy

ORANGEWOOD PARTNERS MAKES STRATEGIC INVESTMENT IN BARRINGTON JAMES

Orangewood and Barrington James | October 06, 2022

Orangewood Partners a long-term focused private investment firm, announced an investment in Barrington James, a leading global recruitment firm that primarily serves the pharmaceutical, biotechnology and medical device sectors. Terms of the transaction were not disclosed. In partnering with Orangewood, Barrington James intends to enhance its global recruiting solutions, expand its client-service capabilities and support its ongoing commitment to developing and utilizing cutting-ed...

Read More
news image

MedTech

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More
news image

Industrial Impact

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More